KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Share-based Compensation (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Share-based Compensation for 9 consecutive years, with $51.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 50.0% year-over-year to $51.0 million, compared with a TTM value of $157.0 million through Dec 2025, up 27.64%, and an annual FY2025 reading of $157.0 million, up 27.64% over the prior year.
  • Share-based Compensation was $51.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $34.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $51.0 million in Q4 2025 and bottomed at $24.0 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $32.2 million, with a median of $31.5 million recorded in 2021.
  • The sharpest move saw Share-based Compensation dropped 23.08% in 2023, then surged 50.0% in 2025.
  • Year by year, Share-based Compensation stood at $33.0 million in 2021, then grew by 9.09% to $36.0 million in 2022, then dropped by 22.22% to $28.0 million in 2023, then increased by 21.43% to $34.0 million in 2024, then soared by 50.0% to $51.0 million in 2025.
  • Business Quant data shows Share-based Compensation for TEVA at $51.0 million in Q4 2025, $34.0 million in Q3 2025, and $38.0 million in Q2 2025.